All Trials

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Enrolling treatment-naive adults with stage IV squamous or non-squamous NSCLC without actionable driver mutations, this trial compares ivonescimab (a bispecific antibody targeting PD-1 and VEGF) plus chemotherapy to pembrolizumab plus chemotherapy. Patients must have ECOG 0–1, at least one measurable noncerebral lesion, and available PD-L1 status, but enrollment is open regardless of PD-L1 expression.

ClinicalTrials.gov ID: NCT05899608

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: This trial enrolls adults with ER+, HER2- advanced or metastatic breast cancer who have progressed on 1–2 lines of endocrine therapy (including a CDK4/6 inhibitor) and randomizes them to receive either palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and degradant, or standard endocrine therapy (fulvestrant or aromatase inhibitor). Key exclusions include symptomatic visceral disease, prior chemotherapy for advanced/metastatic disease, and active CNS involvement.

ClinicalTrials.gov ID: NCT06016738

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: This trial enrolls adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who have developed resistance to prior adjuvant endocrine therapy, with no prior systemic treatment for advanced disease. Patients are randomized to receive either fulvestrant (IM SERD) or giredestrant (oral selective estrogen receptor degrader targeting both wild-type and mutant ER), each combined with a CDK4/6 inhibitor of the investigator's choice.

ClinicalTrials.gov ID: NCT06065748

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Eligible patients are adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer who have not received prior systemic therapy for advanced disease. This trial compares PF-07220060, a selective oral CDK4 inhibitor plus letrozole, with standard first-line CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) plus letrozole.

ClinicalTrials.gov ID: NCT06760637

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with untreated locally advanced/metastatic NSCLC harboring uncommon EGFR PACC mutations are randomized to firmonertinib 240 mg daily (a third‑generation, mutant‑selective covalent EGFR TKI with CNS activity) versus investigator’s choice of osimertinib 80 mg or afatinib 40 mg. Prior adjuvant/neoadjuvant therapy is allowed if >12 months; asymptomatic CNS metastases are eligible.

ClinicalTrials.gov ID: NCT07185997

Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (The HARMONIC Study)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: The trial is for never smoker patients with relapsed advanced primary adenocarcinoma of the lung, featuring actionable genomic alterations, who have progressed after tyrosine kinase inhibitor therapies. It examines the combination of the investigational multi-tyrosine kinase receptor inhibitor LP-300 with carboplatin and pemetrexed, compared to the standard carboplatin-pemetrexed regimen.

ClinicalTrials.gov ID: NCT05456256

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial involves adult patients with advanced solid tumors who have limited treatment options, evaluating the efficacy and safety of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein targeting the PD-1/PD-L1 pathway and activating the IL-2 pathway to enhance tumor-specific T cell activity.

ClinicalTrials.gov ID: NCT06281678

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: The trial targets patients with advanced ALK-positive non-small cell lung cancer who have not previously received specific treatments for NSCLC or ALK, comparing the efficacy of the novel ALK-selective tyrosine kinase inhibitor neladalkib (NVL-655) with alectinib in prolonging progression-free survival.

ClinicalTrials.gov ID: NCT06765109

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic NSCLC harboring KRAS, NRAS, or HRAS mutations (codons 12, 13, or 61) and previously treated with anti-PD-(L)1 and platinum-based chemotherapy (but not RAS inhibitors or docetaxel) are randomized to receive either daraxonrasib, an oral pan-RAS(ON) inhibitor targeting active GTP-bound RAS, or standard docetaxel.

ClinicalTrials.gov ID: NCT06881784

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with advanced NSCLC who have progressed after standard therapies (including prior immunotherapy and platinum-based chemotherapy, or targeted therapy if actionable mutations are present) to receive HLX43, an investigational anti-PD-L1 antibody-drug conjugate linked to a topoisomerase I inhibitor, given intravenously every 3 weeks at two dose levels. Key exclusions include prior topoisomerase I inhibitor exposure, active CNS disease, or small cell/neuroendocrine/sarcomatoid histology.

ClinicalTrials.gov ID: NCT06907615